BG102784A - Synthetic hiv genes - Google Patents

Synthetic hiv genes

Info

Publication number
BG102784A
BG102784A BG102784A BG10278498A BG102784A BG 102784 A BG102784 A BG 102784A BG 102784 A BG102784 A BG 102784A BG 10278498 A BG10278498 A BG 10278498A BG 102784 A BG102784 A BG 102784A
Authority
BG
Bulgaria
Prior art keywords
synthetic
hiv genes
synthetic hiv
codons
genes
Prior art date
Application number
BG102784A
Other languages
Bulgarian (bg)
English (en)
Inventor
John SHIVER
Mary-Ellen Davies
Daniel FREED
Margaret Liu
Helen PERRY
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG102784A publication Critical patent/BG102784A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG102784A 1996-02-22 1998-09-23 Synthetic hiv genes BG102784A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (en) 1996-02-22 1997-02-18 Synthetic hiv genes

Publications (1)

Publication Number Publication Date
BG102784A true BG102784A (en) 1999-05-31

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102784A BG102784A (en) 1996-02-22 1998-09-23 Synthetic hiv genes

Country Status (27)

Country Link
EP (1) EP0904380B1 (is)
JP (1) JP2000505299A (is)
KR (1) KR19990087126A (is)
CN (1) CN1216064A (is)
AR (1) AR005930A1 (is)
AT (1) ATE309366T1 (is)
AU (1) AU729231B2 (is)
BG (1) BG102784A (is)
BR (1) BR9707672A (is)
CO (1) CO4600706A1 (is)
CZ (1) CZ266798A3 (is)
DE (1) DE69734585T2 (is)
EE (1) EE9800257A (is)
ES (1) ES2251734T3 (is)
HR (1) HRP970092A2 (is)
HU (1) HUP9901112A3 (is)
ID (1) ID16021A (is)
IL (1) IL125547A0 (is)
IS (1) IS4814A (is)
NO (1) NO983876L (is)
NZ (1) NZ331161A (is)
PE (1) PE43298A1 (is)
PL (1) PL328730A1 (is)
SK (1) SK112998A3 (is)
TR (1) TR199801615T2 (is)
WO (1) WO1997031115A2 (is)
YU (1) YU35498A (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
EP0912607A2 (en) * 1996-06-21 1999-05-06 Merck & Co., Inc. Vaccines comprising synthetic genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
EP0969862B1 (en) * 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetic hiv gag genes
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
JP2001519663A (ja) 1997-04-04 2001-10-23 ピー． ウィークス、ドナルド 遺伝子導入ジカンバ−分解生物体を製造及び使用するための方法及び材料
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
CN1325646C (zh) 1997-10-20 2007-07-11 Gtc生物治疗学公司 修饰的核酸序列以及增加细胞系统中mRNA水平和蛋白质表达的方法
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
CA2369119A1 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
CA2389633A1 (en) 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
JP2003520786A (ja) * 1999-12-22 2003-07-08 メルク エンド カムパニー インコーポレーテッド コドン最適化ｈｉｖ−１ｐｏｌおよび修飾ｈｉｖ−１ｐｏｌを発現するポリヌクレオチドワクチン
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
JP4472250B2 (ja) * 2000-10-04 2010-06-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 高発現可能遺伝子
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CN100392085C (zh) * 2001-09-20 2008-06-04 葛兰素集团有限公司 疫苗
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
EA020590B1 (ru) 2006-10-16 2014-12-30 Монсанто Текнолоджи Ллс Способы улучшения жизнеспособности растений
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108449A (en) * 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material
EP1170368B1 (en) * 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
NO983876L (no) 1998-10-21
HRP970092A2 (en) 1998-04-30
PE43298A1 (es) 1998-08-29
ATE309366T1 (de) 2005-11-15
AR005930A1 (es) 1999-07-21
CN1216064A (zh) 1999-05-05
PL328730A1 (en) 1999-02-15
DE69734585D1 (de) 2005-12-15
IS4814A (is) 1998-07-30
CZ266798A3 (cs) 1999-03-17
AU729231B2 (en) 2001-01-25
AU2124697A (en) 1997-09-10
ID16021A (id) 1997-08-28
HUP9901112A2 (hu) 1999-07-28
JP2000505299A (ja) 2000-05-09
TR199801615T2 (xx) 1998-11-23
SK112998A3 (en) 2000-04-10
BR9707672A (pt) 1999-04-13
IL125547A0 (en) 1999-03-12
EE9800257A (et) 1999-02-15
KR19990087126A (ko) 1999-12-15
WO1997031115A2 (en) 1997-08-28
HUP9901112A3 (en) 2001-06-28
NO983876D0 (no) 1998-08-21
DE69734585T2 (de) 2006-08-10
NZ331161A (en) 2000-03-27
WO1997031115A3 (en) 1997-10-09
EP0904380A2 (en) 1999-03-31
EP0904380B1 (en) 2005-11-09
CO4600706A1 (es) 1998-05-08
ES2251734T3 (es) 2006-05-01
YU35498A (sh) 1999-07-28

Similar Documents

Publication Publication Date Title
BG102784A (en) Synthetic hiv genes
ZA956709B (en) Ionene polymers containing biologically-active anions
BG101103A (bg) Теломераза при бозайници
PL335050A1 (en) Synthetic genes gag hiv
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DK1009832T3 (da) Cytokin betegnet LERK-6
PT1212358E (pt) Genes sinteticos de papilomavirus humano
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
CA2278028A1 (en) Methods for improving transformation efficiency
DE69413039D1 (de) Prostaglandin rezeptor fp und kodierende dns
EP0656070A4 (en) NUCLEIC ACID SAMPLES FOR LEGIONELLA GENERATIONS.
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
MX9702341A (es) Citoquina designada lerk-6.
DE69726160D1 (de) Neue polymerisierbare acylimidazolidinonmonomere
AU3711597A (en) A novel galanin receptor
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof
AU7357294A (en) Recombinant cladosporium herbarum allergens
CA2251690A1 (en) New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
WO2001039786A3 (en) New uses of suppressive macrophage activation factors
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
EA199800750A1 (ru) Синтетические гены вич